“Valve-In-Valve” Concerns
This article was originally published in The Gray Sheet
Executive Summary
At the meeting, panel members discussed the safety issue of valve-in-valve implantation, wherein one prosthetic valve is implanted inside another one. This is used occasionally in rescue situations during the transcatheter procedure. Edwards has not conducted any pre-clinical studies to assess safety and performance issues for the valve in this context, and the company stresses that it is not seeking an indication for valve-in-valve use. But FDA is nonetheless concerned that if Sapien becomes commercially available, widespread use of the valve-in-valve technique might occur.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.